1 / 5

Effects on Outcomes of Heart Rate Reduction

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial. Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose?. Clinical characteristics of patients by β -blocker status.

carlos-chase
Download Presentation

Effects on Outcomes of Heart Rate Reduction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Systolic Heart failure treatment withthe Ifinhibitor ivabradine Trial Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose?

  2. Clinical characteristics of patients by β-blocker status Swedberg K, et al. J Am Coll Cardiol2012;59:1938-1945.

  3. Effect of ivabradine on outcomes by β-blocker doses **adjusted for interaction between baseline HR and randomisedtreatment Swedberg K, et al. J Am Coll Cardiol2012;59:1938-1945.

  4. HR reduction according toβ-blocker and HR category HR reduction (bpm) from baseline to 28 days with ivabradine* Baseline HR category (bpm) ≥87 80 to <87 75 to <80 72 to <75 Impact of baseline HR on HR reduction with ivabradine <72 No BB BB<25% BB 25-50% BB 50-100% BB ≥100% β-blocker category No impact of BB dose on HR reduction with ivabradine *Placebo corrected Swedberg K, et al. J Am Coll Cardiol2012;59:1938-1945.

  5. Conclusion • In patients with systolic HF treated with guideline-recommended therapies, resting HR remains an important modifiable risk factor in patients treated with β-blockers • When HR≥70 bpm, reduction of heart rate with ivabradine will provide additional clinical benefits regardless of the -blocker dose • The magnitude of HR reduction with ivabradine, beyond that achieved by β-blockers, primarily determines subsequent outcome Swedberg K, et al. J Am Coll Cardiol2012;59:1938-1945.

More Related